View Post

Lilly reports positive PRO from high-risk early breast cancer trial

In Clinical Studies News by Barbara Jacoby

From: clinicaltrialsarena.com Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC).  Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC). The move comes after a primary outcome analysis …

View Post

Veru touts novel breast cancer treatment strategy as drug nears phase 3

In Clinical Studies News by Barbara Jacoby

By: Angus Liu From: fiercebiotech.com Hormone therapies, or endocrine therapies, are widely used to treat breast cancer that is estrogen receptor (ER)-positive, but resistance is a common problem. That has sparked interest in drugs targeting the androgen receptor (AR). But the role of AR in ER-positive disease remains unclear, leading to the development of both AR agonists and antagonists. Now …

View Post

Changing the doses to treat aggressive breast cancer

In In The News by Barbara Jacoby

By: Jim Mertens From: wqad.com Is it possible to get the benefits of chemo without the side effects? Researchers are looking into a new treatment for an aggressive form of breast cancer that is showing some promise. Almost 300,000 American women will hear the words, “You have breast cancer” this year alone. One in four of those breast cancer diagnosis …

View Post

PET Imaging Reveals Which Breast Cancer Patients Won’t Respond to Hormone Therapy

In Clinical Studies News by Barbara Jacoby

By: Whitney J. Palmer From: diagnosticimaging.com Hormone therapy is only effective in roughly half of estrogen receptor-positive cancers. Being able to identify patients that will not respond could save valuable treatment time. The answer to whether hormone replacement therapy will work for a woman with breast cancer likely comes down to whether her estrogen receptors are working – a function …

View Post

Celcuity Announces Breast Cancer Clinical Trial Collaboration with Sarah Cannon and Pfizer to Study New Drug Regimen

In Clinical Studies News by Barbara Jacoby

From: businesswire.com – Trial will evaluate the efficacy and safety of Pfizer’s targeted therapies, VIZIMPRO® and XALKORI®, in patients with metastatic HER2-negative breast cancer selected by Celcuity’s CELsignia Multi-Pathway Activity Test – First clinical trial to treat patients diagnosed with hyperactive HER2 and c-Met signaling breast cancers with matching targeted therapies Celcuity Inc. (Nasdaq: CELC), a clinical stage biotechnology company …

View Post

Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS

In In The News by Barbara Jacoby

From: businesswire.com Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial were presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. …

View Post

YOUR HEALTH: The fear of breast cancer returning

In In The News by Barbara Jacoby

By: Jim Mertens From: wqad.com It’s a huge challenge for women after breast cancer treatment: living with the fear of recurrence They’ve either heard the words, “you are cured”, or they are still being monitored and treated for the disease. Almost four million women in the United States are breast cancer survivors. But for many women, there’s overwhelming fear the …

View Post

FDA OKs Pembrolizumab in Advanced TNBC

In Clinical Studies News by Barbara Jacoby

By: Ian Ingram From: medpagetoday.com Checkpoint inhibitor nabs accelerated approval for PD-L1 expressors The FDA on Friday granted accelerated approval to pembrolizumab (Keytruda) for treating triple-negative breast cancer (TNBC) patients with metastatic or locally recurrent unresectable disease. TNBC becomes the astonishing 18th cancer indication for pembrolizumab, which was first approved in 2014 for advanced or unresectable melanoma. Pembrolizumab, a PD-1-directed …

View Post

Maverick Therapeutics to Use Inivata’s Liquid Biopsy Assay in Phase I/II Clinical Study

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter 115 From: precisiononcologynews.com Inivata said on Thursday that it has partnered with Maverick Therapeutics to use Inivata’s Radar (Residual Disease and Recurrence) assay to detect and monitor residual disease and recurrence in patients enrolled in Maverick’s Phase I/II clinical study for its MVC-101 drug candidate. As part of the study, the team will use Radar to monitor circulating tumor …